SMHGF (Simcere Pharmaceutical Group) Ending Cash Position: $499 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMHGF Simcere Pharmaceutical Group Ltd SMHGF
94 GF Score
Price $1.49
GF Value $1.35
View Full Analysis

What is Simcere Pharmaceutical Group Ending Cash Position?

Simcere Pharmaceutical Group SMHGF 94 Ending Cash Position is $499 Mil as of Dec. 2025. GuruFocus rates SMHGF with a GF Score™ of 94/100 and a GF Value™ of $1.35.

Simcere Pharmaceutical Group's Ending Cash Position for the quarter that ended in Dec. 2025 was $499 Mil.

Simcere Pharmaceutical Group's quarterly Ending Cash Position increased from Dec. 2024 ($268 Mil) to Jun. 2025 ($372 Mil) and increased from Jun. 2025 ($372 Mil) to Dec. 2025 ($499 Mil).

Simcere Pharmaceutical Group's annual Ending Cash Position declined from Dec. 2023 ($281 Mil) to Dec. 2024 ($268 Mil) but then increased from Dec. 2024 ($268 Mil) to Dec. 2025 ($499 Mil).

Simcere Pharmaceutical Group Ending Cash Position Related Terms

Simcere Pharmaceutical Group Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Ending Cash Position Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 152.79 237.86 281.11 268.19 498.65

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.11 379.75 268.19 371.92 498.65
SMHGF
94GF Score
Simcere Pharmaceutical Group Ltd SMHGF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Simcere Pharmaceutical Group's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=277.229+221.42
=499

Simcere Pharmaceutical Group's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=380.513+118.136
=499

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $499 Mil mean?
Simcere Pharmaceutical Group (SMHGF) has a Ending Cash Position of $499 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Ending Cash Position too high?
Simcere Pharmaceutical Group's current Ending Cash Position is $499 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Ending Cash Position compare to ZTS?
Simcere Pharmaceutical Group's Ending Cash Position of $499 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Ending Cash Position is $499 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (SMHGF) has a current Ending Cash Position of $499 Mil. The stock's GF Value™ is $1.35, compared to a current price of $1.49 — trading 10.3% above its estimated fair value. The current Ending Cash Position is $499 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current Ending Cash Position is $499 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.49 is trading 10.3% above its estimated GF Value™ of $1.35.

Key valuation signals for SMHGF:

  • Ending Cash Position: $499 Mil
  • GF Value™: $1.35 vs. price of $1.49 (10.3% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for SMHGF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$1.35
GF Value